Postexposure Treatment of Marburg Virus Infection

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2010 Jul 1

PMID 20587184

Citations 56

Authors

Thomas W Geisbert

Lisa E Hensley

Joan B Geisbert

Anders Leung

Joshua C Johnson

Allen Grolla

Heinz Feldmann

Affiliations

Soon will be listed here.

Abstract

Rhesus monkeys are protected from disease when a recombinant vesicular stomatitis virus-based vaccine is administered 20-30 min after infection with Marburg virus. We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection.

Citing Articles

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.

Camargos V, Rossi S, Juelich T, Smith J, Vasilakis N, Freiberg A Viruses. 2024; 16(8).

PMID: 39205155 PMC: 11359148. DOI: 10.3390/v16081181.

An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.

de La Vega M, Xiii A, Massey S, Spengler J, Kobinger G, Woolsey C Expert Opin Drug Discov. 2024; 19(10):1185-1211.

PMID: 39090822 PMC: 11466704. DOI: 10.1080/17460441.2024.2386100.

Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.

Bushmaker T, Feldmann F, Lovaglio J, Saturday G, Griffin A, ODonnell K J Infect Dis. 2023; 228(Suppl 7):S721-S729.

PMID: 37474155 PMC: 10651186. DOI: 10.1093/infdis/jiad280.

A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.

Woolsey C, Strampe J, Fenton K, Agans K, Martinez J, Borisevich V J Infect Dis. 2023; 228(Suppl 7):S712-S720.

PMID: 37290053 PMC: 10651203. DOI: 10.1093/infdis/jiad207.

Computed Tomography Imaging for Monitoring of Marburg Virus Disease: a Nonhuman Primate Proof-Of-Concept Study.

Sword J, Lee J, Castro M, Solomon J, Aiosa N, Reza S Microbiol Spectr. 2023; 11(3):e0349422.

PMID: 37036346 PMC: 10269526. DOI: 10.1128/spectrum.03494-22.

References

Feldmann H, Jones S, Daddario-DiCaprio K, Geisbert J, Stroher U, Grolla A . Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007; 3(1):e2. PMC: 1779298. DOI: 10.1371/journal.ppat.0030002. View

Kortepeter M, Martin J, Rusnak J, Cieslak T, Warfield K, Anderson E . Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis. 2008; 14(6):881-7. PMC: 2600302. DOI: 10.3201/eid1406.071489. View

Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78(10):5458-65. PMC: 400370. DOI: 10.1128/jvi.78.10.5458-5465.2004. View

Tuffs A . Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ. 2009; 338:b1223. DOI: 10.1136/bmj.b1223. View

Geisbert T, Hensley L, Jahrling P, Larsen T, Geisbert J, Paragas J . Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003; 362(9400):1953-8. DOI: 10.1016/S0140-6736(03)15012-X. View

Gonchar N, PSHENICHNOV V, Pokhodiaev V, Lopatov K, Firsova I . [The sensitivity of different experimental animals to the Marburg virus]. Vopr Virusol. 1991; 36(5):435-7. View

Geisbert T, Hensley L, Kagan E, Yu E, Geisbert J, Daddario-DiCaprio K . Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006; 193(12):1650-7. PMC: 7110204. DOI: 10.1086/504267. View

Daddario-DiCaprio K, Geisbert T, Stroher U, Geisbert J, Grolla A, Fritz E . Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006; 367(9520):1399-404. DOI: 10.1016/S0140-6736(06)68546-2. View

Enterlein S, Warfield K, Swenson D, Stein D, Smith J, Gamble C . VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006; 50(3):984-93. PMC: 1426423. DOI: 10.1128/AAC.50.3.984-993.2006. View

10.

Warfield K, Swenson D, Olinger G, Nichols D, Pratt W, Blouch R . Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006; 2(1):e1. PMC: 1326218. DOI: 10.1371/journal.ppat.0020001. View

11.

Hensley L, Stevens E, Yan S, Geisbert J, Macias W, Larsen T . Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007; 196 Suppl 2:S390-9. DOI: 10.1086/520598. View

12.

Geisbert T, Daddario-DiCaprio K, Williams K, Geisbert J, Leung A, Feldmann F . Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008; 82(11):5664-8. PMC: 2395203. DOI: 10.1128/JVI.00456-08. View